Senores Pharmaceuticals Ltd

Senores Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Senores Pharmaceuticals Ltd

₹ 712 -0.54%
19 Sep - close price
senorespharma.com BSE: 544319 NSE: SENORES
About

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]

Key Points

Business Overview:[1]
SPL is global research driven pharmaceutical company which develops and manufactures
pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs

Website BSE NSE
  • Market Cap ₹ 3,280 Cr.
  • Current Price ₹ 712
  • High / Low ₹ 751 / 435
  • Stock P/E 56.0
  • Book Value ₹ 171
  • Dividend Yield 0.00 %
  • ROCE 11.4 %
  • ROE 11.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Debtor days have improved from 177 to 114 days.

Cons

  • Stock is trading at 4.17 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost
  • Working capital days have increased from 21.7 days to 88.2 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE IPO BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Mar 2024 Jun 2024 Dec 2024 Mar 2025 Jun 2025
79 102 80 103 114 138
64 80 59 77 95 104
Operating Profit 15 22 21 26 19 34
OPM % 19% 22% 27% 25% 17% 25%
1 2 0 5 12 3
Interest 2 3 5 6 5 5
Depreciation 3 4 4 4 5 6
Profit before tax 10 18 13 20 21 26
Tax % 31% 19% 19% 20% 13% 20%
7 14 11 16 18 21
EPS in Rs 2.37 5.23 3.23 3.73 3.87 4.28
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
14 35 215 398
12 23 173 309
Operating Profit 2 13 42 90
OPM % 14% 36% 19% 23%
0 4 3 19
Interest 1 2 9 22
Depreciation 1 2 10 17
Profit before tax 1 12 25 71
Tax % 13% 32% -31% 17%
1 8 33 58
EPS in Rs 1.01 8.59 10.31 12.72
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 204%
TTM: 86%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 290%
TTM: 86%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 15%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 9 10 31 46
Reserves 28 36 174 740
15 63 258 315
8 23 160 126
Total Liabilities 59 131 622 1,227
7 27 235 301
CWIP 8 34 97 172
Investments 15 16 0 0
29 53 289 754
Total Assets 59 131 622 1,227

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
-10 -1 -26 -46
-24 -48 -54 -429
36 46 87 573
Net Cash Flow 2 -3 8 98

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 506 228 191 114
Inventory Days 135 89 184 232
Days Payable 324 388 556 275
Cash Conversion Cycle 317 -71 -182 70
Working Capital Days 359 -7 -16 88
ROCE % 18% 12% 11%

Shareholding Pattern

Numbers in percentages

21 Recently
Dec 2024Mar 2025Jun 2025
45.77% 45.78% 45.78%
4.25% 4.17% 3.66%
11.77% 9.66% 9.51%
38.20% 40.39% 41.03%
No. of Shareholders 49,51837,65336,389

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls